Biocept reports second quarter 2021 financial results

San diego--(business wire)--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended june 30, 2021 and provides a business update. “we are reporting profitability for the first half of 2021 on revenues of nearly $30 million driven by rt-pcr covid-19 testing,” said michael nall, biocept's president and ceo. “revenues of $12.0 million for the quarter reflect the anticipated sequential quart
BIOC Ratings Summary
BIOC Quant Ranking